 | • レポートコード：QFJ1-5097 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療機器 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、良性前立腺肥大症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品用、低侵襲手術用、レーザー治療用、その他）、用途別市場規模（病院、外来手術センター、専門クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・良性前立腺肥大症治療の市場動向 ・企業の競争状況、市場シェア ・良性前立腺肥大症治療の種類別市場規模と予測2016-2027（医薬品用、低侵襲手術用、レーザー治療用、その他） ・良性前立腺肥大症治療の用途別市場規模と予測2016-2027（病院、外来手術センター、専門クリニック、その他） ・良性前立腺肥大症治療の北米市場規模2016-2027（アメリカ、カナダ） ・良性前立腺肥大症治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・良性前立腺肥大症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・良性前立腺肥大症治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・良性前立腺肥大症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Abbott、Allergan plc、Astellas Pharma、Asahi Kasei Corporation、Boehringer Ingelheim GmbH、GlaxoSmithKline、Pfizer、Sanofi、Teva Pharmaceutical Industries、Merck、Boston Scientific Corporation、Teleflex Incorporated、Endo International、Urologix、LISA Laser、Olympus） ・結論 |
Market Analysis and Insights: Global Benign Prostatic Hyperplasia Treatment Market
The global Benign Prostatic Hyperplasia Treatment market size is projected to reach US$ 8438.6 million by 2027, from US$ 6476.6 million in 2020, at a CAGR of 3.4% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Benign Prostatic Hyperplasia Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Benign Prostatic Hyperplasia Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Benign Prostatic Hyperplasia Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Benign Prostatic Hyperplasia Treatment market.
Global Benign Prostatic Hyperplasia Treatment Scope and Market Size
Benign Prostatic Hyperplasia Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Drug Class
Minimally Invasive Surgeries
Laser Therapy
Others
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Abbott
Allergan plc
Astellas Pharma
Asahi Kasei Corporation
Boehringer Ingelheim GmbH
GlaxoSmithKline
Pfizer
Sanofi
Teva Pharmaceutical Industries
Merck
Boston Scientific Corporation
Teleflex Incorporated
Endo International
Urologix
LISA Laser
Olympus
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Class
1.2.3 Minimally Invasive Surgeries
1.2.4 Laser Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Treatment Market Perspective (2016-2027)
2.2 Benign Prostatic Hyperplasia Treatment Growth Trends by Regions
2.2.1 Benign Prostatic Hyperplasia Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Benign Prostatic Hyperplasia Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Benign Prostatic Hyperplasia Treatment Industry Dynamic
2.3.1 Benign Prostatic Hyperplasia Treatment Market Trends
2.3.2 Benign Prostatic Hyperplasia Treatment Market Drivers
2.3.3 Benign Prostatic Hyperplasia Treatment Market Challenges
2.3.4 Benign Prostatic Hyperplasia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Treatment Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia Treatment Players by Revenue (2016-2021)
3.1.2 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Benign Prostatic Hyperplasia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Treatment Revenue
3.4 Global Benign Prostatic Hyperplasia Treatment Market Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Treatment Revenue in 2020
3.5 Benign Prostatic Hyperplasia Treatment Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia Treatment Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia Treatment Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia Treatment Historic Market Size by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Type (2022-2027)
5 Benign Prostatic Hyperplasia Treatment Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia Treatment Historic Market Size by Application (2016-2021)
5.2 Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
6.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Type
6.2.1 North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
6.2.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
6.2.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
6.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Application
6.3.1 North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
6.3.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
6.3.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
6.4 North America Benign Prostatic Hyperplasia Treatment Market Size by Country
6.4.1 North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021)
6.4.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
7.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type
7.2.1 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
7.2.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
7.2.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
7.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application
7.3.1 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
7.3.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
7.3.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
7.4 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country
7.4.1 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021)
7.4.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type
8.2.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region
8.4.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
9.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type
9.2.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
9.3 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application
9.3.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
9.4 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country
9.4.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type
10.2.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country
10.4.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Benign Prostatic Hyperplasia Treatment Introduction
11.1.4 Abbott Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.1.5 Abbott Recent Development
11.2 Allergan plc
11.2.1 Allergan plc Company Details
11.2.2 Allergan plc Business Overview
11.2.3 Allergan plc Benign Prostatic Hyperplasia Treatment Introduction
11.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.2.5 Allergan plc Recent Development
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Details
11.3.2 Astellas Pharma Business Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Treatment Introduction
11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.3.5 Astellas Pharma Recent Development
11.4 Asahi Kasei Corporation
11.4.1 Asahi Kasei Corporation Company Details
11.4.2 Asahi Kasei Corporation Business Overview
11.4.3 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Introduction
11.4.4 Asahi Kasei Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.4.5 Asahi Kasei Corporation Recent Development
11.5 Boehringer Ingelheim GmbH
11.5.1 Boehringer Ingelheim GmbH Company Details
11.5.2 Boehringer Ingelheim GmbH Business Overview
11.5.3 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Introduction
11.5.4 Boehringer Ingelheim GmbH Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.5.5 Boehringer Ingelheim GmbH Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.6.5 GlaxoSmithKline Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Benign Prostatic Hyperplasia Treatment Introduction
11.7.4 Pfizer Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.7.5 Pfizer Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Benign Prostatic Hyperplasia Treatment Introduction
11.8.4 Sanofi Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.8.5 Sanofi Recent Development
11.9 Teva Pharmaceutical Industries
11.9.1 Teva Pharmaceutical Industries Company Details
11.9.2 Teva Pharmaceutical Industries Business Overview
11.9.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Introduction
11.9.4 Teva Pharmaceutical Industries Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.9.5 Teva Pharmaceutical Industries Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Benign Prostatic Hyperplasia Treatment Introduction
11.10.4 Merck Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.10.5 Merck Recent Development
11.11 Boston Scientific Corporation
11.11.1 Boston Scientific Corporation Company Details
11.11.2 Boston Scientific Corporation Business Overview
11.11.3 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Introduction
11.11.4 Boston Scientific Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.11.5 Boston Scientific Corporation Recent Development
11.12 Teleflex Incorporated
11.12.1 Teleflex Incorporated Company Details
11.12.2 Teleflex Incorporated Business Overview
11.12.3 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Introduction
11.12.4 Teleflex Incorporated Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.12.5 Teleflex Incorporated Recent Development
11.13 Endo International
11.13.1 Endo International Company Details
11.13.2 Endo International Business Overview
11.13.3 Endo International Benign Prostatic Hyperplasia Treatment Introduction
11.13.4 Endo International Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.13.5 Endo International Recent Development
11.14 Urologix
11.14.1 Urologix Company Details
11.14.2 Urologix Business Overview
11.14.3 Urologix Benign Prostatic Hyperplasia Treatment Introduction
11.14.4 Urologix Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.14.5 Urologix Recent Development
11.15 LISA Laser
11.15.1 LISA Laser Company Details
11.15.2 LISA Laser Business Overview
11.15.3 LISA Laser Benign Prostatic Hyperplasia Treatment Introduction
11.15.4 LISA Laser Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.15.5 LISA Laser Recent Development
11.16 Olympus
11.16.1 Olympus Company Details
11.16.2 Olympus Business Overview
11.16.3 Olympus Benign Prostatic Hyperplasia Treatment Introduction
11.16.4 Olympus Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
11.16.5 Olympus Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drug Class
Table 3. Key Players of Minimally Invasive Surgeries
Table 4. Key Players of Laser Therapy
Table 5. Key Players of Others
Table 6. Global Benign Prostatic Hyperplasia Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Benign Prostatic Hyperplasia Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Benign Prostatic Hyperplasia Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Benign Prostatic Hyperplasia Treatment Market Share by Regions (2016-2021)
Table 10. Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Benign Prostatic Hyperplasia Treatment Market Share by Regions (2022-2027)
Table 12. Benign Prostatic Hyperplasia Treatment Market Trends
Table 13. Benign Prostatic Hyperplasia Treatment Market Drivers
Table 14. Benign Prostatic Hyperplasia Treatment Market Challenges
Table 15. Benign Prostatic Hyperplasia Treatment Market Restraints
Table 16. Global Benign Prostatic Hyperplasia Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Benign Prostatic Hyperplasia Treatment Market Share by Players (2016-2021)
Table 18. Global Top Benign Prostatic Hyperplasia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia Treatment as of 2020)
Table 19. Ranking of Global Top Benign Prostatic Hyperplasia Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Benign Prostatic Hyperplasia Treatment Product Solution and Service
Table 23. Date of Enter into Benign Prostatic Hyperplasia Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Benign Prostatic Hyperplasia Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Abbott Company Details
Table 64. Abbott Business Overview
Table 65. Abbott Benign Prostatic Hyperplasia Treatment Product
Table 66. Abbott Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 67. Abbott Recent Development
Table 68. Allergan plc Company Details
Table 69. Allergan plc Business Overview
Table 70. Allergan plc Benign Prostatic Hyperplasia Treatment Product
Table 71. Allergan plc Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 72. Allergan plc Recent Development
Table 73. Astellas Pharma Company Details
Table 74. Astellas Pharma Business Overview
Table 75. Astellas Pharma Benign Prostatic Hyperplasia Treatment Product
Table 76. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 77. Astellas Pharma Recent Development
Table 78. Asahi Kasei Corporation Company Details
Table 79. Asahi Kasei Corporation Business Overview
Table 80. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product
Table 81. Asahi Kasei Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 82. Asahi Kasei Corporation Recent Development
Table 83. Boehringer Ingelheim GmbH Company Details
Table 84. Boehringer Ingelheim GmbH Business Overview
Table 85. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product
Table 86. Boehringer Ingelheim GmbH Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 87. Boehringer Ingelheim GmbH Recent Development
Table 88. GlaxoSmithKline Company Details
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product
Table 91. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 92. GlaxoSmithKline Recent Development
Table 93. Pfizer Company Details
Table 94. Pfizer Business Overview
Table 95. Pfizer Benign Prostatic Hyperplasia Treatment Product
Table 96. Pfizer Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 97. Pfizer Recent Development
Table 98. Sanofi Company Details
Table 99. Sanofi Business Overview
Table 100. Sanofi Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 101. Sanofi Recent Development
Table 102. Teva Pharmaceutical Industries Company Details
Table 103. Teva Pharmaceutical Industries Business Overview
Table 104. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product
Table 105. Teva Pharmaceutical Industries Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 106. Teva Pharmaceutical Industries Recent Development
Table 107. Merck Company Details
Table 108. Merck Business Overview
Table 109. Merck Benign Prostatic Hyperplasia Treatment Product
Table 110. Merck Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 111. Merck Recent Development
Table 112. Boston Scientific Corporation Company Details
Table 113. Boston Scientific Corporation Business Overview
Table 114. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product
Table 115. Boston Scientific Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 116. Boston Scientific Corporation Recent Development
Table 117. Teleflex Incorporated Company Details
Table 118. Teleflex Incorporated Business Overview
Table 119. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product
Table 120. Teleflex Incorporated Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 121. Teleflex Incorporated Recent Development
Table 122. Endo International Company Details
Table 123. Endo International Business Overview
Table 124. Endo International Benign Prostatic Hyperplasia Treatment Product
Table 125. Endo International Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 126. Endo International Recent Development
Table 127. Urologix Company Details
Table 128. Urologix Business Overview
Table 129. Urologix Benign Prostatic Hyperplasia Treatment Product
Table 130. Urologix Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 131. Urologix Recent Development
Table 132. LISA Laser Company Details
Table 133. LISA Laser Business Overview
Table 134. LISA Laser Benign Prostatic Hyperplasia Treatment Product
Table 135. LISA Laser Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 136. LISA Laser Recent Development
Table 137. Olympus Company Details
Table 138. Olympus Business Overview
Table 139. Olympus Benign Prostatic Hyperplasia Treatment Product
Table 140. Olympus Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
Table 141. Olympus Recent Development
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Benign Prostatic Hyperplasia Treatment Market Share by Type: 2020 VS 2027
Figure 2. Drug Class Features
Figure 3. Minimally Invasive Surgeries Features
Figure 4. Laser Therapy Features
Figure 5. Others Features
Figure 6. Global Benign Prostatic Hyperplasia Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Ambulatory Surgical Centers Case Studies
Figure 9. Specialty Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Benign Prostatic Hyperplasia Treatment Report Years Considered
Figure 12. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Benign Prostatic Hyperplasia Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Benign Prostatic Hyperplasia Treatment Market Share by Regions (2022-2027)
Figure 16. Global Benign Prostatic Hyperplasia Treatment Market Share by Players in 2020
Figure 17. Global Top Benign Prostatic Hyperplasia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia Treatment Revenue in 2020
Figure 19. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
Figure 23. North America Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
Figure 24. North America Benign Prostatic Hyperplasia Treatment Market Share by Country (2016-2027)
Figure 25. United States Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
Figure 29. Europe Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
Figure 30. Europe Benign Prostatic Hyperplasia Treatment Market Share by Country (2016-2027)
Figure 31. Germany Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share by Region (2016-2027)
Figure 41. China Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Benign Prostatic Hyperplasia Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Abbott Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 61. Allergan plc Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 62. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 63. Asahi Kasei Corporation Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 64. Boehringer Ingelheim GmbH Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 65. GlaxoSmithKline Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 66. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 67. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 68. Teva Pharmaceutical Industries Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 69. Merck Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 70. Boston Scientific Corporation Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 71. Teleflex Incorporated Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 72. Endo International Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 73. Urologix Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 74. LISA Laser Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 75. Olympus Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
良性前立腺過形成の治療のグローバル市場：規模・現状・予測2019-2025 In 2018, the global Benign Prostatic Hyperplasia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Benign Prostatic Hyperplasia Treatment status, future forecast, growth oppor…- 良性前立腺過形成の治療のグローバル市場：規模・現状・予測2019-2025 In 2018, the global Benign Prostatic Hyperplasia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Benign Prostatic Hyperplasia Treatment status, future forecast, growth oppor…
- 世界の良性前立腺肥大症治療装置市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Benign Prostatic Hyperplasia Treatment Equipments Market The global Benign Prostatic Hyperplasia Treatment Equipments market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard …
- 世界の良性前立腺肥大症薬市場規模・現状・予測（2021年-2027年） The goal of Benign prostate hyperplasia drugs is to reduce morbidity and prevent complications.Agents used include alpha-adrenergic blockers, 5-alpha-reductase inhibitors, phosphodiesterase -5 inhibitors and various combinations. Market Analysis and Insights: Global Benign Prostate Hyperplasia Drugs…
- 世界の前立腺動脈塞栓術（PAE）市場規模・現状・予測（2021年-2027年） Prostatic artery embolization(PAE) is a minimally invasive operation for the treatment of prostatic hyperplasia and hypertrophy, which can significantly improve urination symptoms and improve the quality of life of patients.The operation is interventional therapy, which is to place the microcatheter…